“Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” 

Friends of Cancer Research’s President and CEO Dr. Jeff Allen, along with fellow healthcare leaders, testified at the House Energy and Commerce Health Subcommittee hearing, “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.”  The hearing focused on the important impact regulation of LDT’s could have on patients and providers, ensuring higher standards and higher quality care. Dr. Allen’s testimony (available here) focused on how improved transparency of test performance would help identify and manage potential variability and ensure consistency in the information being utilized by patients and healthcare providers.

Friends of Cancer Research thanks the House Energy and Commerce Committee for their leadership on this issue. It is paramount to ensure that the FDA has the support and tools it needs to effectively regulate LDT’s, impacting the lives of millions of Americans who rely on the safety and accuracy of these tests for access to new treatments and cures.